NASDAQ:AGEN Agenus (AGEN) Stock Price, News & Analysis $4.95 -0.05 (-1.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.81▼$5.1050-Day Range$4.58▼$17.7352-Week Range$4.41▼$27.20Volume204,622 shsAverage Volume711,717 shsMarket Capitalization$103.95 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Agenus alerts: Email Address Agenus MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside112.1% Upside$10.50 Price TargetShort InterestBearish12.94% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.19Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($10.87) to ($10.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.06 out of 5 starsMedical Sector166th out of 910 stocksBiological Products, Except Diagnostic Industry18th out of 155 stocks 4.1 Analyst's Opinion Consensus RatingAgenus has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageAgenus has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Agenus' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.94% of the float of Agenus has been sold short.Short Interest Ratio / Days to CoverAgenus has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Agenus has recently increased by 21.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAgenus does not currently pay a dividend.Dividend GrowthAgenus does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgenus has received a 72.61% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agenus is -0.93. Previous Next 1.2 News and Social Media Coverage News SentimentAgenus has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Agenus this week, compared to 3 articles on an average week.Search InterestOnly 34 people have searched for AGEN on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agenus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Agenus is held by insiders.Percentage Held by Institutions61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Agenus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agenus are expected to grow in the coming year, from ($10.87) to ($10.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agenus is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agenus is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Agenus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Agenus Stock (NASDAQ:AGEN)Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Read More AGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGEN Stock News HeadlinesSeptember 7 at 2:01 AM | americanbankingnews.comCritical Contrast: Metagenomi (NASDAQ:MGX) vs. Agenus (NASDAQ:AGEN)September 5 at 1:53 AM | americanbankingnews.comAnalyzing Agenus (NASDAQ:AGEN) & Compass Therapeutics (NASDAQ:CMPX)September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 25, 2024 | stockhouse.comThe Schall Law Firm Is Seeking Help From Agenus Inc Shareholders For An Inquiry Into Securities Law InfractionsAugust 24, 2024 | stockhouse.comAgenus Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Is Looking For Investors To AssistAugust 17, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGENAugust 16, 2024 | uk.investing.comAgenus shares target cut, maintains buy on setback with the FDAAugust 15, 2024 | nz.finance.yahoo.comAJ8.DU,0P0001JT35,0 (AJ8.DU)September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 13, 2024 | markets.businessinsider.comAgenus: Strong Clinical Potential Amidst Regulatory Challenges and Revised Market Entry ForecastAugust 12, 2024 | finance.yahoo.comSaponiQx and InvivoGen Launch STIMULON Cultured Plant Cell QS-21 Adjuvant for Commercial PurchaseAugust 9, 2024 | finance.yahoo.comAgenus Announces Appointment of Tom Harrison to Board of DirectorsAugust 9, 2024 | markets.businessinsider.comAgenus Hold Rating: Balancing Phase 2 Progress with Regulatory Challenges and UncertaintyAugust 9, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGENAugust 8, 2024 | markets.businessinsider.comAgenus is about to announce its earnings — here's what to expectAugust 6, 2024 | benzinga.comAgenus (NASDAQ:AGEN) Stock Quotes, Forecast and News SummaryAugust 6, 2024 | bizjournals.comBMS hands tumor-fighting antibody back to Lexington biotechAugust 5, 2024 | finance.yahoo.comBristol Myers sends TIGIT drug back to AgenusSee More Headlines Receive AGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AGEN CUSIP00847G70 CIK1098972 Webagenusbio.com Phone(781) 674-4400Fax781-674-4200Employees440Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$18.00 Low Stock Price Target$7.00 Potential Upside/Downside+112.1%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($12.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,760,000.00 Net Margins-144.94% Pretax Margin-144.94% Return on EquityN/A Return on Assets-77.23% Debt Debt-to-Equity RatioN/A Current Ratio0.37 Quick Ratio0.37 Sales & Book Value Annual Sales$159.63 million Price / Sales0.65 Cash FlowN/A Price / Cash FlowN/A Book Value($10.24) per share Price / Book-0.48Miscellaneous Outstanding Shares20,999,000Free Float20,033,000Market Cap$103.95 million OptionableOptionable Beta1.36 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Founder, Executive Chairman & CEO Comp: $1.34MMs. Christine M. Klaskin (Age 58)VP of Finance, Principal Financial Officer & Principal Accounting Officer Comp: $407.44kDr. Steven J. O'Day M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $970.98kCraig WinterChief Information OfficerMr. Zack ArmenHead of Investor RelationsMs. Tracy Mazza ClementeChief People OfficerMr. Alfred DadsonChief Manufacturing OfficerMr. Eric HumesChief Quality OfficerDr. Todd Jude Yancey M.D.Member of Advisory Board & Chief Strategic AdvisorDr. Robin G. Taylor M.B.A.Ph.D., Chief Commercial OfficerMore ExecutivesKey CompetitorsPrecision BioSciencesNASDAQ:DTILPoseida TherapeuticsNASDAQ:PSTXAdaptimmune TherapeuticsNASDAQ:ADAPOyster Point PharmaNASDAQ:OYSTSutro BiopharmaNASDAQ:STROView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 29,853,012 shares on 8/19/2024Ownership: 1.241%Susquehanna International Group LLPBought 47,900 shares on 8/16/2024Ownership: 0.000%Susquehanna Fundamental Investments LLCBought 62,703 shares on 8/15/2024Ownership: 0.299%AQR Capital Management LLCSold 1,173,911 shares on 8/15/2024Ownership: 0.073%Point72 Asia Singapore Pte. Ltd.Bought 6,343 shares on 8/15/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions AGEN Stock Analysis - Frequently Asked Questions How have AGEN shares performed this year? Agenus' stock was trading at $16.5580 at the beginning of the year. Since then, AGEN shares have decreased by 70.1% and is now trading at $4.95. View the best growth stocks for 2024 here. How were Agenus' earnings last quarter? Agenus Inc. (NASDAQ:AGEN) posted its earnings results on Thursday, August, 8th. The biotechnology company reported ($2.52) earnings per share for the quarter, missing the consensus estimate of ($1.33) by $1.19. The biotechnology company earned $23.51 million during the quarter, compared to analysts' expectations of $64.73 million. When did Agenus' stock split? Agenus's stock reverse split on Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Garo H. Armen's approval rating as Agenus' CEO? 2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Agenus' major shareholders? Agenus' top institutional investors include Point72 Asset Management L.P. (1.24%), Renaissance Technologies LLC (1.21%), Federated Hermes Inc. (0.55%) and Bank of New York Mellon Corp (0.43%). Insiders that own company stock include Agenus Inc, Garo H Armen, Steven J O'day and Christine M Klaskin. View institutional ownership trends. How do I buy shares of Agenus? Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA). This page (NASDAQ:AGEN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
